Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD‑1 inhibitor KEYTRUDA (pembrolizumab) has been approved by China's National Medical Products Administration (NMPA) in combination with chemotherapy as neoadjuvant…

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

Peijia Medical Wins NMPA Approval for GeminiOne TEER System – A Novel Transcatheter Edge‑to‑Edge Repair Device for Mitral Regurgitation in China
CompanyMedical Device

Peijia Medical Wins NMPA Approval for GeminiOne TEER System – A Novel Transcatheter Edge‑to‑Edge Repair Device for Mitral Regurgitation in China

TransThera Sciences' YOCHANRA (Tinengotinib) Receives First Prescription in China – World's First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma
CompanyDrug

TransThera Sciences’ YOCHANRA (Tinengotinib) Receives First Prescription in China – World’s First Approved Targeted Therapy for Post‑FGFR‑Inhibitor Cholangiocarcinoma

Haisco's HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma
CompanyDrug

Haisco’s HSK42360‑Na Proposed for CDE Breakthrough Therapy Designation – Next‑Generation BRAF Inhibitor Targets V600‑Mutant High‑Grade Glioma

Astellas' PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval
CompanyDrug

Astellas’ PADCEV Plus Keytruda Receives Positive CHMP Opinion – Perioperative Muscle‑Invasive Bladder Cancer Regimen Nears EU Approval

Novo Nordisk's FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization
CompanyDrug

Novo Nordisk’s FREHEMGO (Denecimig) Receives Positive CHMP Opinion – Next‑Generation Hemophilia A Prophylaxis Nears EU Authorization

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Santo Therapeutics and PolyGene officially signed a strategic cooperation framework agreement to initiate comprehensive and deep collaboration in the field of gene therapy delivery technologies. The partnership centers on HPAE non‑viral delivery vectors, the novel BrPERfect transfection reagent platform, and…

Hengrui's SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement

Hengrui’s SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Huadong Medicine's Sinclair Secures Exclusive China Collaboration for Maybio's iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet
CompanyDeals

Huadong Medicine’s Sinclair Secures Exclusive China Collaboration for Maybio’s iPSC‑Engineered MB007 ECM Collagen – Regenerative Aesthetics Bet

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership
CompanyDeals

WuXi XDC Licenses WuXiTecan‑2 Payload‑Linker Technology to Ona Therapeutics – Exclusive Global ADC Deal Deepens Partnership

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion
CompanyDeals

Dualitas Signs Research Collaboration and License Deal with Roche – Bispecific Antibody Partnership Valued at Up to US$1 Billion

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing
CompanyDeals

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

HitGen Inc. (SHA: 688222) announced that its wholly‑owned Hong Kong subsidiary, HitGen (HK) Ltd., together with OrbiMed Asia Partners, LAV, Panku Capital Limited, and other investors, has jointly invested in…

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly's AI/ML Drug Discovery Platform
CompanyDeals

GenScript Biotech Collaborates with Lilly TuneLab – Pairing Large‑Scale Wet‑Lab Validation with Eli Lilly’s AI/ML Drug Discovery Platform

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development
CompanyDeals

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development

Novartis Exercises Exclusive Option to Acquire Global Rights to Sironax Brain Delivery Platform – USD 125 Million Transaction Targets Blood‑Brain Barrier Breakthrough for CNS Diseases
CompanyDeals

Novartis Exercises Exclusive Option to Acquire Sironax Brain Delivery Platform in USD 125 Million Transaction

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target
CompanyDeals

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target

- Advertisement -
Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

CompanyDeals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
CompanyDeals

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

CompanyDeals

NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China
Policy / Regulatory

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China

China's National Medical Products Administration (NMPA) issued the Announcement on Further Optimizing the Requirements for Application Materials of Process Validation for Innovative Chemical Drugs (Draft for Comments), seeking public feedback…

China's NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies
Policy / Regulatory

China’s NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies

NMPA Issues Medical Device GMP Inspection Guidelines – Revised Production Quality Standards Take Effect November 1, 2026
Medical DevicePolicy / Regulatory

NMPA Issues Medical Device GMP Inspection Guidelines – Revised Production Quality Standards Take Effect November 1, 2026

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

More News

XtalPi's LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology
Others

XtalPi’s LCC Technologies Signs Drug Discovery Collaboration with Stanford University – Chiral Chemistry Meets Disease Biology

Nutshell Therapeutics' NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2
CompanyDrug

Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development
CompanyDrug

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development

CDE Includes Beijing Toll Biotech's TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential
CompanyDrug

CDE Includes Beijing Toll Biotech’s TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

NMPA Grants Priority Review to Everest Medicines' Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China
CompanyDrug

NMPA Grants Priority Review to Everest Medicines’ Manufacturing‑Transfer NDA for VELSIPITY (Etrasimod) – Localizing Production of Its Approved Ulcerative Colitis Therapy in China

Tempest Therapeutics Secures Exclusive Option to License Senlang's CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma
CompanyDeals

Tempest Therapeutics Secures Exclusive Option to License Senlang’s CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media
CompanyDeals

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media

NMPA Accepts Qilu Pharmaceutical's Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI
CompanyDrug

NMPA Accepts Qilu Pharmaceutical’s Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI

Show More